(RTTNews) - Yet another busy week of earnings is over. Following are few of the companies, which issued upbeat projections during the week ended November 6.

GEO Group - A sound outlook

GEO Group Inc. (GEO), which reported better-than-expected third-quarter profit Monday, reaffirmed its fourth-quarter earnings outlook and increased its full-year guidance on the strength of its sound operational and financial results across its diversified business units.

The company provides private corrections and detention management, health, and mental health services to federal, state and local government agencies.

For the fourth-quarter, GEO expects earnings, excluding items, to range between $0.38 and $0.39 per share, on revenue of $313 million-$318 million. The fourth-quarter earnings outlook excludes $0.08 per share in a one-time, after-tax charge related to the early extinguishment of debt as well as $0.03 per share in after-tax start-up/transition expenses. Wall Street analysts have earnings estimate pegged at $0.39 per share and revenue at $311.51 million.

Looking ahead to full-year 2009, GEO boosted its pro forma earnings guidance to a range of $1.40-$1.41 per share, up from its previous revised outlook of $1.37- $1.39 per share. Analysts have revised their projections within the past seven days, pushing the consensus earnings estimate by 4 cents to $1.41 per share.

The company also increased its revenue forecast for 2009 to a range of $1.143 billion-$1.148 billion from its prior outlook of $1.113 billion-$1.123 billion. Wall Street analysts have a consensus revenue estimate of $1.14 billion.

GEO gained more than 2% over the past five days to close Friday's trading at $21.59.
Valeant Pharma Intl. - A healthy dose of optimism

Valeant Pharmaceuticals International (VRX), which posted better-than-expected adjusted third-quarter earnings helped by 31% revenue growth Monday, also increased its 2009 cash earnings per share outlook.

For 2009, the company now expects cash earnings per share to range between $2.10 and $2.20, up from its prior guidance of $1.90-$2.10 per share.

Valeant's pipeline candidates include Retigabine for the treatment of epilepsy and pain, Taribavirin of the treatment of chronic hepatitis C, and dermatology compounds.

Retigabine is being developed in collaboration with GlaxoSmithKline plc. (GSK). The company completed both the New Drug Application and the Marketing Authorisation Application submissions for Retigabine on October 30, 2009.

To receive FREE breaking news email alerts for HealthSouth Corp. and others in your portfolio

 1   2   3   4   5   6   7   8   9   10   11   12   13   14   Next Page